# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
5-year survival rate of 82.6% and 73% reduction in overall risk of death (hazard ratio of 0.27) are the strongest Multikine eff...
CEL-SCI Corporation (NYSE:CVM) today reported it has received a decision letter from the United Kingdom's Healthcare Produc...
CEL-SCI (AMEX:CVM) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.11) by 27....
CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE: CVM), a cancer immunotherapy company, today announced t...